What is Cagrilintide?

A long-acting amylin receptor agonist developed by Novo Nordisk, primarily studied as a fixed-combination with semaglutide under the working name CagriSema.

Is Cagrilintide available now?

No — investigational only. The standalone molecule is not on the market; the CagriSema combination is in Phase 3 trials with read-outs expected mid-to-late decade.

How does it compare to GLP-1 agonists alone?

Phase 2 combination data showed approximately −17% weight loss at 20 weeks, more than semaglutide monotherapy alone. Amylin agonism is complementary to GLP-1 — it suppresses post-prandial glucagon and slows gastric emptying.

Cagrilintide — Peptidepedia

MOLECULAR INFORMATION

Molecular information

Type: Long-acting amylin receptor agonist · weekly subcutaneous · investigational

Cagrilintide is Novo Nordisk’s long-acting amylin analogue, developed primarily as a fixed-combination with semaglutide under the working name CagriSema. Amylin agonism complements GLP-1 by suppressing post-prandial glucagon and slowing gastric emptying.

Status

Phase 3 (REDEFINE) of CagriSema underway for obesity and T2DM
Cagrilintide monotherapy positioned secondary to the combination
Not authorised

Why we grade it B

Phase 2 monotherapy showed ~10% weight loss at 26 weeks; combination Phase 1b data showed ~17% at 20 weeks. Mechanistically sound, sponsor-funded but well-powered. Phase 3 readouts will determine whether grade rises.

References

REDEFINE programme 2024

CagriSema combination (cagrilintide + semaglutide) in obesity — Phase 3 ongoing, target population 60,000+ across multiple sub-trials

Frequently asked questions

What is Cagrilintide?: A long-acting amylin receptor agonist developed by Novo Nordisk, primarily studied as a fixed-combination with semaglutide under the working name CagriSema.
Is Cagrilintide available now?: No — investigational only. The standalone molecule is not on the market; the CagriSema combination is in Phase 3 trials with read-outs expected mid-to-late decade.
How does it compare to GLP-1 agonists alone?: Phase 2 combination data showed approximately −17% weight loss at 20 weeks, more than semaglutide monotherapy alone. Amylin agonism is complementary to GLP-1 — it suppresses post-prandial glucagon and slows gastric emptying.